In Vivo Evaluation of a Novel Chitosan-Polycaprolactone Based Mucoadhesive Gastro-Retentive Sustained Release Drug Delivery System for Milnacipran HCl.
anomalous release
bioavailability
canine-based controlled delivery
milnacipran
mucoadhesion
Journal
AAPS PharmSciTech
ISSN: 1530-9932
Titre abrégé: AAPS PharmSciTech
Pays: United States
ID NLM: 100960111
Informations de publication
Date de publication:
07 Jan 2020
07 Jan 2020
Historique:
received:
11
09
2019
accepted:
09
12
2019
entrez:
9
1
2020
pubmed:
9
1
2020
medline:
4
6
2020
Statut:
epublish
Résumé
The study was aimed to develop a gastro-retentive mucoadhesive sustained release matrix formulation for milnacipran HCl (MCN) by using the design of experiment (DoE). The gastro-retentive swellable mucoadhesive matrix tablets were prepared by modified solvent-based wet granulation through mixing milnacipran (MCN), chitosan low molecular weight (CH-LM), chitosan medium molecular weight (CH-MM), and polycaprolactone (PCL). Optimization of the formulation was carried out via DoE. Formulations were characterized by DSC, FTIR, and in vitro drug release testing. In vitro mucoadhesive studies were performed on rabbit's intestinal mucosa. In vivo drug release studies were performed on dogs. Optimized matrix formulations showed no significant interaction among the polymers and MCN, confirmed by DSC and FTIR, and were characterized as swellable controlled release matrix systems. The optimized formulations M
Identifiants
pubmed: 31912249
doi: 10.1208/s12249-019-1606-6
pii: 10.1208/s12249-019-1606-6
doi:
Substances chimiques
Delayed-Action Preparations
0
Polyesters
0
polycaprolactone
24980-41-4
Chitosan
9012-76-4
Milnacipran
G56VK1HF36
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Références
Malik R, Garg T, Goyal AK, Rath G. Polymeric nanofibers: targeted gastro-retentive drug delivery systems. J Drug Target. 2015;23(2):109–24.
doi: 10.3109/1061186X.2014.965715
Kaur R, Garg T, Malik B, Gupta UD, Gupta P, Rath G, et al. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Delivery. 2016;23(3):872–7.
doi: 10.3109/10717544.2014.920428
Kulkarni S, Kulkarni R, Jadhav P. Tiwari A. Google Patents: Controlled release pharmaceutical compositions of milnacipran; 2014.
English C, Rey JA, Rufin C. Milnacipran (Savella), a treatment option for fibromyalgia. Pharm Ther. 2010;35(5):261.
Kyle JA, Dugan BD, Testerman KK. New drug approvals: milnacipran for treatment of fibromyalgia. Ann Pharmacother. 2010;44(9):1422–9.
doi: 10.1345/aph.1P218
Ratnakar NC, Gohel MC. Formulation and eveluation of milnacipran HCl controlled release osmotic tablets. Pharma Sci Monit. 2018;9(1).
Luo Y, Teng Z, Li Y, Wang Q. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr Polym. 2015;122:221–9.
doi: 10.1016/j.carbpol.2014.12.084
Hussain T, Shahzad MK, Hayat K, Hussain K, Bukhari NI. Simple and sensitive colorimetric method for the determination of milnacipran in bulk and swellable matrix tablets. Pharm Chem J. 2016;50(5):346–52.
doi: 10.1007/s11094-016-1449-3
Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12(3):263–71.
doi: 10.1208/s12248-010-9185-1
Luppi B, Bigucci F, Abruzzo A, Corace G, Cerchiara T, Zecchi V. Freeze-dried chitosan/pectin nasal inserts for antipsychotic drug delivery. Eur J Pharm Biopharm. 2010;75(3):381–7.
doi: 10.1016/j.ejpb.2010.04.013
Puozzo C, Filaquier C, Zorza G. Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection. J Chromatogr B Anal Technol Biomed Life Sci. 2004;806(2):221–8.
doi: 10.1016/j.jchromb.2004.03.063
Parejiya PB, Movaliya VR, Barot BS, Modi D, Shelat PK, Shukla A. Quantitative determination of milnacipran HCl in rabbit plasma by HPLC and its application to pharmacokinetics study. J Liq Chromatogr Relat Technol. 2014;37(1):99–111.
doi: 10.1080/10826076.2012.734002
Allen P, Bennett K, Heritage B (2018) SPSS statistics: a practical guide with student resource access 12 months: Cengage AU
USP. The United States Pharmacopeia. US Pharmacopeial Convention Inc., Rockville, MD,USA: 2748–27512005
Hussain T, Saeed T, Mumtaz AM, Javaid Z, Abbas K, Awais A, et al. Effect of two hydrophobic polymers on the release of gliclazide from their matrix tablets. Acta Pol Pharm. 2013;70(4):749–57.
pubmed: 23923399
Pickering G, Macian N, Delage N, Picard P, Cardot J-M, Sickout-Arondo S, et al. Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study. Drug Des Devel Ther. 2018;12:2485.
doi: 10.2147/DDDT.S162810
Parejiya PB, Barot BS, Patel HK, Chorawala MR, Shelat PK, Shukla A. In vivo performance evaluation and establishment of IVIVC for osmotic pump based extended release formulation of milnacipran HCl. Biopharm Drug Dispos. 2013;34(4):227–35.
doi: 10.1002/bdd.1840
Gaspar MC, Grégoire N, Sousa JJ, Pais AA, Lamarche I, Gobin P, et al. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. Eur J Pharm Sci. 2016;93:184–91.
doi: 10.1016/j.ejps.2016.08.024
Gopal PR, Prabakar AC, Chandrashekar E, Somaiah PV. Synthesis and characterization of process related impurities of (±)-milnacipran. J Chin Chem Soc. 2013;60(6):639–44.
doi: 10.1002/jccs.201200484
Wu C-S. A comparison of the structure, thermal properties, and biodegradability of polycaprolactone/chitosan and acrylic acid grafted polycaprolactone/chitosan. Polymer. 2005;46(1):147–55.
doi: 10.1016/j.polymer.2004.11.013
Abdolmohammadi S, Siyamak S, Ibrahim NA, Yunus WMZW, Rahman MZA, Azizi S, et al. Enhancement of mechanical and thermal properties of polycaprolactone/chitosan blend by calcium carbonate nanoparticles. Int J Mol Sci. 2012;13(4):4508–22.
doi: 10.3390/ijms13044508
Bauer M, Megret C, Lamure A, Lacabanne C, Fauran-Clavel MJ. Differential scanning calorimetry study of the interaction of antidepressant drugs, noradrenaline, and 5-hydroxytryptamine with a membrane model. J Pharm Sci. 1990;79(10):897–901.
doi: 10.1002/jps.2600791011
Senda T, He Y, Inoue Y. Biodegradable blends of poly (ε-caprolactone) with α-chitin and chitosan: specific interactions, thermal properties and crystallization behavior. Polym Int. 2002;51(1):33–9.
doi: 10.1002/pi.793
Sun Y, Cui F, Shi K, Wang J, Niu M, Ma R. The effect of chitosan molecular weight on the characteristics of spray-dried methotrexate-loaded chitosan microspheres for nasal administration. Drug Dev Ind Pharm. 2009;35(3):379–86.
doi: 10.1080/03639040802395185
Siepmann J, Peppas N. Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics (the “sequential layer” model). Pharm Res. 2000;17(10):1290–8.
doi: 10.1023/A:1026455822595
Peppas NA, Narasimhan B. Mathematical models in drug delivery: how modeling has shaped the way we design new drug delivery systems. J Control Release. 2014;190:75–81.
doi: 10.1016/j.jconrel.2014.06.041
Omwancha WS, Mallipeddi R, Valle BL, Neau SH. Chitosan as a pore former in coated beads for colon specific drug delivery of 5-ASA. Int J Pharm. 2013;441(1):343–51.
doi: 10.1016/j.ijpharm.2012.11.022
Sahoo S, Sasmal A, Nanda R, Phani A, Nayak P. Synthesis of chitosan–polycaprolactone blend for control delivery of ofloxacin drug. Carbohydr Polym. 2010;79(1):106–13.
doi: 10.1016/j.carbpol.2009.07.042
Abruzzo A, Bigucci F, Cerchiara T, Cruciani F, Vitali B, Luppi B. Mucoadhesive chitosan/gelatin films for buccal delivery of propranolol hydrochloride. Carbohydr Polym. 2012;87(1):581–8.
doi: 10.1016/j.carbpol.2011.08.024
Vemula SK, Veerareddy PR, Devadasu VR. Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets. Eur J Drug Metab Pharmacokinet. 2015;40(3):301–11.
doi: 10.1007/s13318-014-0210-0
Tang M, Hu P, Huang S, Zheng Q, Yu H, He Y. Development of an extended-release formulation for apremilast and a level A in vitro–in vivo correlation study in beagle dogs. Chem Pharm Bull. 2016;64(11):1607–15.
doi: 10.1248/cpb.c16-00519